Top

International Urology and Nephrology

Published in:

01-04-2014 | Nephrology - Original Paper

Perirenal fat associated with microalbuminuria in obese rats

Authors: Ningning Hou, Fang Han, Mingling Wang, Na Huang, Jiangang Zhao, Xue Liu, Xiaodong Sun

Published in: International Urology and Nephrology | Issue 4/2014

Abstract

Purpose

To determine whether perirenal fat is associated with increased urinary albumin excretion and whether perirenal fat affects renal vascular endothelial function in obese rats.

Methods

Wistar rats were randomly divided into normal and obesity group, which were fed with normal and high-fat diet, respectively. Blood and urine samples were collected. Endothelial function of the aorta was determined by measuring endothelium-dependent vasodilatation. Renal tissues were collected for CD34 immunohistochemistry and free fatty acids (FFA) measurement. Levels of glomerular nitric oxide (NO) and reactive oxygen species (ROS) were measured.

Results

After 24 weeks, plasma FFA, high-sensitivity C-reactive protein, and malondialdehyde levels were elevated and were significantly higher in renal venous blood than in jugular venous blood in obese rats. Urinary albumin/creatinine ratio, glomerular CD34 expression, glomerular ROS level, and renal cortex FFA levels were higher in obese rats. Endothelial dysfunction was more severe in the infra-renal aorta than in the thoracic aorta in obese rats. Plasma adiponectin and glomerular NO levels were lower in obese rats.

Conclusion

Perirenal fat is associated with increased urinary albumin excretion in obese rats. The mechanism may be renal vascular endothelial dysfunction caused by increased oxidative stress and activation of inflammatory molecular pathways due to elevated FFA and low adiponectin levels.

Hurt RT, Frazier TH, McClave SA, Kaplan LM (2011) Obesity epidemic: overview, pathophysiology, and the intensive care unit conundrum. JPEN J Parenter Enteral Nutr 35(5 Suppl):4S–13SPubMedCrossRef

Rokholm B, Baker JL, Sorensen TI (2010) The levelling off of the obesity epidemic since the year 1999—a review of evidence and perspectives. Obes Rev 11(12):835–846PubMedCrossRef

Klausen KP, Parving HH, Scharling H, Jensen JS (2009) Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol (Oxf) 71(1):40–45CrossRef

Kopple JD, Feroze U (2011) The effect of obesity on chronic kidney disease. J Ren Nutr 21(1):66–71PubMedCrossRef

Weisinger JR, Kempson RL, Eldridge FL, Swenson RS (1974) The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 81(4):440–447PubMedCrossRef

Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59(4):1498–1509PubMedCrossRef

Foster MC, Hwang SJ, Massaro JM, Hoffmann U, DeBoer IH, Robins SJ et al (2011) Association of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study. Obesity (Silver Spring) 19(6):1284–1289CrossRef

Sun X, Han F, Miao W, Hou N, Cao Z, Zhang G (2013) Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients. Int Urol Nephrol 45(6):1589–1595PubMedCrossRef

Lamacchia O, Nicastro V, Camarchio D, Valente U, Grisorio R, Gesualdo L et al (2011) Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients. Nephrol Dial Transplant 26(3):892–898PubMedCrossRef

10.

Han F, Hou N, Miao W, Sun X (2013) Correlation of ultrasonographic measurement of intrarenal arterial resistance index with microalbuminuria in nonhypertensive, nondiabetic obese patients. Int Urol Nephrol 45(4):1039–1045PubMedCrossRef

11.

Sun X, Han F, Yi J, Hou N, Cao Z (2013) The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes in vivo and in vitro. Mol Med Rep 7(5):1636–1640PubMed

12.

Lee RM, Lu C, Su LY, Werstuck G, Gao YJ (2009) Effects of hyperglycemia on the modulation of vascular function by perivascular adipose tissue. J Hypertens 27(1):118–131PubMedCrossRef

13.

Sun X, Yu Y, Han L (2013) High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats. Int Urol Nephrol 45(4):1197–1207PubMedCrossRef

14.

Kono T, Saito M, Kinoshita Y, Satoh I, Shinbori C, Satoh K (2006) Real-time monitoring of nitric oxide and blood flow during ischemia-reperfusion in the rat testis. Mol Cell Biochem 286(1–2):139–145PubMedCrossRef

15.

Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T et al (2005) Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67(5):1890–1898PubMedCrossRef

16.

Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE (2003) A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 41(4):733–741PubMedCrossRef

17.

Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M et al (2006) Larger waist circumference is a predictive factor for the occurrence of microalbuminuria in a non-diabetic population. Arch Mal Coeur Vaiss 99(7–8):660–662PubMed

18.

Sharma K (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Investig 118(5):1645PubMedCentralPubMed

19.

Sharma K (2009) The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 76(2):145–148PubMedCrossRef

20.

Li Y, Sun X, Yu Y (2013) Serum fetuin-A levels related with microalbuminuria in diet-induced obese rats. Biomed Res Int 2013:795103PubMedCentralPubMed

21.

Kern PA (2003) Adiponectin expression from human adipose tissue relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 52(7):1779–1785PubMedCrossRef

22.

Yamauchi T, Kadowaki T (2008) Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 32(Suppl 7):S13–S18CrossRef

Title: Perirenal fat associated with microalbuminuria in obese rats
Authors: Ningning Hou
Fang Han
Mingling Wang
Na Huang
Jiangang Zhao
Xue Liu
Xiaodong Sun
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 4/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-014-0656-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

Predictive factors for the development of chronic renal insufficiency after renal surgery: a multicenter study

The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL

Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men

Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters

Anaemia in a renal allograft recipient: an unusual cause

Comparison of erythropoietin and sildenafil protective role against ischemia/reperfusion injury of the testis in adult rats

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials